Inactive Instrument

SenzaGen AB Share Price Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for SenzaGen AB

Financials

Sales 2024 * 67.35M 6.35M 529M Sales 2025 * 91.85M 8.66M 722M Capitalization 211M 19.9M 1.66B
Net income 2024 * -11M -1.04M -86.45M Net income 2025 * 1M 94.34K 7.86M EV / Sales 2024 * 2.78 x
Net cash position 2024 * 23.8M 2.25M 187M Net cash position 2025 * 22M 2.08M 173M EV / Sales 2025 * 2.06 x
P/E ratio 2024 *
-14.9 x
P/E ratio 2025 *
-44.7 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.78%
More Fundamentals * Assessed data

Latest transcript on SenzaGen AB

Managers TitleAgeSince
Chief Executive Officer 50 01/18/01
Director of Finance/CFO 63 01/16/01
Chief Tech/Sci/R&D Officer 42 01/14/01
Members of the board TitleAgeSince
Founder 76 18/10/18
Director/Board Member 59 15/14/15
Director/Board Member 62 01/20/01
More insiders
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Calendar
More about the company